Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipin Das Villgran

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Familial Cancer|September 11, 2020
Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areasGeorge Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, et al.
Familial Cancer|January 11, 2021
Comparison of universal screening in major lynch-associated tumors: a systematic review of literatureGeorge Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, et al.
Critical Care Nursing Quarterly|May 26, 2022
Acute Respiratory FailureVipin Das Villgran, Caitlan Lyons, Adeel Nasrullah, et al.
The Breast Journal|August 29, 2017
Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancerAju Mathew, Tala Achkar, Shira Abberbock, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Familial Cancer|September 11, 2020
Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areasGeorge Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, et al.
Familial Cancer|January 11, 2021
Comparison of universal screening in major lynch-associated tumors: a systematic review of literatureGeorge Kunnackal John, Vipin Das Villgran, Christine Caufield-Noll, et al.
Critical Care Nursing Quarterly|May 26, 2022
Acute Respiratory FailureVipin Das Villgran, Caitlan Lyons, Adeel Nasrullah, et al.
The Breast Journal|August 29, 2017
Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancerAju Mathew, Tala Achkar, Shira Abberbock, et al.
Pageof 1